日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

In silico & in vitro approaches suggest osteoclastogenesis induction underlying fractures in Entrectinib-treated children

计算机模拟和体外实验表明,恩曲替尼治疗儿童的骨折可能与破骨细胞生成诱导有关。

Ehnert, Sabrina; Nüssler, Andreas K; Schulz, Kevin A; Cardenas, Alison; Meneses-Lorente, Georgina; McCallum, Sam; Fürst-Recktenwald, Sabine; Roth, Adrian

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations

儿童肿瘤患者恩曲替尼剂量确认:药代动力学考量

Meneses-Lorente, Georgina; Guerini, Elena; Mercier, Francois; Parrott, Neil; Kowalski, Karey; Chow-Maneval, Edna; Buchheit, Vincent; Bergthold, Guillaume; Fox, Elizabeth; Phipps, Alex; Djebli, Nassim

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

恩曲替尼用于治疗携带 NTRK、ROS1 或 ALK 异常的实体瘤或原发性中枢神经系统肿瘤的儿童和青少年(STARTRK-NG)

Desai, Ami V; Robinson, Giles W; Gauvain, Karen; Basu, Ellen M; Macy, Margaret E; Maese, Luke; Whipple, Nicholas S; Sabnis, Amit J; Foster, Jennifer H; Shusterman, Suzanne; Yoon, Janet; Weiss, Brian D; Abdelbaki, Mohamed S; Armstrong, Amy E; Cash, Thomas; Pratilas, Christine A; Corradini, Nadège; Marshall, Lynley V; Farid-Kapadia, Mufiza; Chohan, Saibah; Devlin, Clare; Meneses-Lorente, Georgina; Cardenas, Alison; Hutchinson, Katherine E; Bergthold, Guillaume; Caron, Hubert; Chow Maneval, Edna; Gajjar, Amar; Fox, Elizabeth

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

抗 CSF-1R emactuzumab 与抗 PD-L1 atezolizumab 联合用于既往未接受过或已接受过免疫检查点阻断治疗的晚期实体瘤患者

Gomez-Roca, Carlos; Cassier, Philippe; Zamarin, Dmitriy; Machiels, Jean-Pascal; Perez Gracia, Jose Luis; Stephen Hodi, F; Taus, Alvaro; Martinez Garcia, Maria; Boni, Valentina; Eder, Joseph P; Hafez, Navid; Sullivan, Ryan; Mcdermott, David; Champiat, Stephane; Aspeslagh, Sandrine; Terret, Catherine; Jegg, Anna-Maria; Jacob, Wolfgang; Cannarile, Michael A; Ries, Carola; Korski, Konstanty; Michielin, Francesca; Christen, Randolph; Babitzki, Galina; Watson, Carl; Meneses-Lorente, Georgina; Weisser, Martin; Rüttinger, Dominik; Delord, Jean-Pierre; Marabelle, Aurelien

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)

体外和临床研究旨在确定恩曲替尼(一种神经营养酪氨酸受体激酶 (NTRK) 小分子抑制剂)的药物相互作用潜力。

Meneses-Lorente, Georgina; Fowler, Stephen; Guerini, Elena; Kowalski, Karey; Chow-Maneval, Edna; Yu, Li; Mercier, Francois; Ullah, Mohammed; Umehara, Kenichi; Brink, Andreas; Buchheit, Vincent; Zwanziger, Elke; Phipps, Alex; Djebli, Nassim

Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors

对健康志愿者和实体瘤患者体内恩曲替尼及其活性代谢物M5的药代动力学特征进行研究

Meneses-Lorente, Georgina; Bentley, Darren; Guerini, Elena; Kowalski, Karey; Chow-Maneval, Edna; Yu, Li; Brink, Andreas; Djebli, Nassim; Mercier, Francois; Buchheit, Vincent; Phipps, Alex

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

抗 CSF-1R 抗体 emactuzumab 联合 CD40 激动剂 selicrelumab 治疗晚期实体瘤患者的 Ib 期研究

Machiels, Jean-Pascal; Gomez-Roca, Carlos; Michot, Jean-Marie; Zamarin, Dmitriy; Mitchell, Tara; Catala, Gaetan; Eberst, Lauriane; Jacob, Wolfgang; Jegg, Anna-Maria; Cannarile, Michael A; Watson, Carl; Babitzki, Galina; Korski, Konstanty; Klaman, Irina; Teixeira, Priscila; Hoves, Sabine; Ries, Carola; Meneses-Lorente, Georgina; Michielin, Francesca; Christen, Randolph; Rüttinger, Dominik; Weisser, Martin; Delord, Jean-Pierre; Cassier, Philippe

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

一项针对晚期/转移性实体瘤患者的emactuzumab单药或联合紫杉醇治疗的I期研究显示,免疫抑制性M2样巨噬细胞被清除。

Gomez-Roca, C A; Italiano, A; Le Tourneau, C; Cassier, P A; Toulmonde, M; D'Angelo, S P; Campone, M; Weber, K L; Loirat, D; Cannarile, M A; Jegg, A-M; Ries, C; Christen, R; Meneses-Lorente, G; Jacob, W; Klaman, I; Ooi, C-H; Watson, C; Wonde, K; Reis, B; Michielin, F; Rüttinger, D; Delord, J-P; Blay, J-Y

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy

抗 HER2/3 联合治疗引起的腹泻毒性机制研究

Annie Moisan, Francesca Michielin, Wolfgang Jacob, Sven Kronenberg, Sabine Wilson, Blandine Avignon, Régine Gérard, Fethallah Benmansour, Christine McIntyre, Georgina Meneses-Lorente, Max Hasmann, Andreas Schneeweiss, Martin Weisser, Céline Adessi

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

一项Ib期研究评估了抗HER3抗体lumretuzumab联合抗HER2抗体pertuzumab和紫杉醇治疗HER3阳性、HER2低表达转移性乳腺癌的安全性和临床活性。

Schneeweiss, Andreas; Park-Simon, Tjoung-Won; Albanell, Joan; Lassen, Ulrik; Cortés, Javier; Dieras, Veronique; May, Marcus; Schindler, Christoph; Marmé, Frederik; Cejalvo, Juan Miguel; Martinez-Garcia, Maria; Gonzalez, Iria; Lopez-Martin, Jose; Welt, Anja; Levy, Christelle; Joly, Florence; Michielin, Francesca; Jacob, Wolfgang; Adessi, Céline; Moisan, Annie; Meneses-Lorente, Georgina; Racek, Tomas; James, Ian; Ceppi, Maurizio; Hasmann, Max; Weisser, Martin; Cervantes, Andrés